CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - MGI Pharma, Inc. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, today provided highlights of data presentations made during the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting. Dacogen (decitabine) for Injection was the subject of five posters including the presentation of efficacy data in older patients with acute myelogenous leukemia (AML) and activity observed in patients with refractory acute lymphocytic leukemia (ALL). Gliadel Wafer (polifeprosan 20 with carmustine implant) was the subject of two posters with one detailing the impact of multimodal therapy that included Gliadel implantation, followed by treatment with radiation and concurrent temozolomide plus rotational chemotherapy, on survival in patients with primary glioblastoma. A poster discussion provided updated response and survival data from a randomized phase 2 clinical trial of Irofulven (MGI 114; hydroxymethylacylfulvene) in hormone refractory prostate cancer (HRPC) patients who failed docetaxel treatment. In addition to two posters, Aloxi(R) (palonosetron hydrochloride) Injection was the subject of a published abstract describing study results that differentiate the molecular interaction of Aloxi with the 5-HT3 receptor. These data provide new insight into the receptor binding mechanisms that may explain the enhanced protection from chemotherapy-induced nausea and vomiting (CINV) observed with Aloxi in clinical trials.

"The data presentations at ASCO demonstrate our commitment to advancing the discovery of clinical attributes that distinguish each of the oncology products in our portfolio," said Mary Lynne Hedley, Ph.D., Executive Vice President and Chief Scientific Officer of MGI PHARMA. "We look forward to advancing the scientific understanding of our product candidates and the presentation of data at future medical meetings."

Aloxi(R) Injection<
'"/>

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting